Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Opa1 Overexpression Protects from Early-Onset Mpv17−/−-Related Mouse Kidney Disease

  • Luna-Sanchez, Marta
  • Benincá, Cristiane
  • Cerutti, Raffaele
  • Brea-Calvo, Gloria
  • Yeates, Anna
  • Scorrano, Luca
  • Zeviani, Massimo
  • Viscomi, Carlo
Moderate overexpression of Opa1, the master regulator of mitochondrial cristae morphology, significantly improved mitochondrial damage induced by drugs, surgical denervation, or oxidative phosphorylation (OXPHOS) defects due to specific impairment of a single mitochondrial respiratory chain complex. Here, we investigated the effectiveness of this approach in the Mpv17−/− mouse, characterized by profound, multisystem mitochondrial DNA (mtDNA) depletion. After the crossing with Opa1tg mice, we found a surprising anticipation of the severe, progressive focal segmental glomerulosclerosis, previously described in Mpv17−/− animals as a late-onset clinical feature (after 12–18 months of life). In contrast, Mpv17−/− animals from this new “mixed” strain died at 8–9 weeks after birth because of severe kidney failure However, Mpv17−/−::Opa1tg mice lived much longer than Mpv17−/− littermates and developed the kidney dysfunction much later. mtDNA content and OXPHOS activities were significantly higher in Mpv17−/−::Opa1tg than in Mpv17−/− kidneys and similar to those for wild-type (WT) littermates. Mitochondrial network and cristae ultrastructure were largely preserved in Mpv17−/−::Opa1tg versus Mpv17−/− kidney and isolated podocytes. Mechanistically, the protective effect of Opa1 overexpression in this model was mediated by a block in apoptosis due to the stabilization of the mitochondrial cristae. These results demonstrate that strategies aiming at increasing Opa1 expression or activity can be effective against mtDNA depletion syndromes., Our research was supported by the Telethon Foundation, Italy (grant GGP19007), ERC Advanced grant FP7-3222424, and a grant from the NRJ-Institut de France (to M.Z.); Associazione Luigi Comini ONLUS; and a core grant from the Medical Research Council, UK (grant MC_UU_00015/5)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Perturbed Redox Signaling Exacerbates a Mitochondrial Myopathy

  • Dogan, Sukru Anil
  • Cerutti, Raffaele
  • Benincá, Cristiane
  • Brea-Calvo, Gloria
  • Trevor Jacobs, Howard
  • Zeviani, Massimo
  • Szibor, Marten
  • Viscomi, Carlo
Alternative oxidases (AOXs) bypass respiratory complexes III and IV by transferring electrons from coenzyme Q directly to O2. They have therefore been proposed as a potential therapeutic tool for mitochondrial diseases. We crossed the severely myopathic skeletal muscle-specific COX15 knockout (KO) mouse with an AOX-transgenic mouse. Surprisingly, the double KO-AOX mutants had decreased lifespan and a substantial worsening of the myopathy compared with KO alone. Decreased ROS production in KO-AOX versus KO mice led to impaired AMPK/PGC-1α signaling and PAX7/MYOD-dependent muscle regeneration, blunting compensatory responses. Importantly, the antioxidant N-acetylcysteine had a similar effect, decreasing the lifespan of KO mice. Our findings have major implications for understanding pathogenic mechanisms in mitochondrial diseases and for the design of therapies, highlighting the benefits of ROS signaling and the potential hazards of antioxidant treatment., This work was supported by MRC-QQR Grant 2015-2020 (M.Z.), ERC Advanced Grants ERC FP7-322424 (M.Z.) and 232738 (H.T.J.), NRJ-Institut de France (M.Z.), and Academy of Finland grants 272376 and 256615 (H.T.J.). S.A.D. was supported by an EMBO Long-Term Fellowship (ALTF 856-2014) and EU (LTFCOFUND2013, GA-2013-609409). We are grateful to the personnel at ARES and Phenomics Animal Care Facilities for the support in managing our colonies. The BF-F3, SC-71, and BA-F8 monoclonal antibodies developed by Prof. Stefano Schiaffino, University of Padova, Italy, were obtained from the Developmental Studies Hybridoma Bank; created by the NICHD of the NIH; and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Two independent respiratory chains adapt OXPHOS performance to glycolytic switch, Metabolic regulation of MRC organization

  • Fernandez-Vizarra, Erika
  • López-Calcerrada, Sandra
  • Sierra-Magro, Ana
  • Pérez-Pérez, Rafael
  • Formosa, Luke E.
  • Hock, Daniella H.
  • Illescas, María
  • Peñas, Ana
  • Brischigliaro, Michele
  • Ding, Shujing
  • Fearnley, Ian M.
  • Tzoulis, Charalampos
  • Pitceathly, Robert D. S.
  • Arenas, Joaquín
  • Martín, Miguel Ángel
  • Stroud, David A.
  • Zeviani, Massimo
  • Ryan, Michael T.
  • Ugalde, Cristina
65 p.-7 fig.-1 tab.-7 fig. suppl., The structural and functional organization of the mitochondrial respiratory chain (MRC) remains intensely debated. Here, we show the co-existence of two separate MRC organizations in human cells and postmitotic tissues, C-MRC and S-MRC, defined by the preferential expression of three COX7A subunit isoforms, COX7A1/2 and SCAFI (COX7A2L). COX7A isoforms promote the functional reorganization of distinct co-existing MRC structures to prevent metabolic exhaustion and MRC deficiency. Notably, prevalence of each MRC organization is reversibly regulated by the activation state of the pyruvate dehydrogenase complex (PDC). Under oxidative conditions, the C-MRC is bioenergetically more efficient, whereas the S-MRC preferentially maintains oxidative phosphorylation (OXPHOS) upon metabolic rewiring toward glycolysis. We show a link between the metabolic signatures converging at the PDC and the structural and functional organization of the MRC, challenging the widespread notion of the MRC as a single functional unit and concluding that its structural heterogeneity warrants optimal adaptation to metabolic function., We thank E. Lamantea and the biobank “Cell line and DNA Bank of Genetic Movement Disorders and Mitochondrial Diseases,” member of the Telethon Network of Genetic Biobanks (project no. GTB12001), funded by Telethon Italy and the EuroBioBank network, for the PDH-deficient fibroblasts. We thank M.G. Hanna, co-lead for the London NHS England Highly Specialised Service for Rare Mitochondrial Disorders, for access to patient-derived tissue. We are grateful to A. Sanz and K. Tokatlidis (University of Glasgow) and C. Viscomi and T. Calì (University of Padova) for their support, as well as to C. Romualdi (University of Padova) and C. Doerrier (Oroboros Instruments) for insightful revision and discussions about the respirometry datasets. Research was funded by Instituto de Salud Carlos III-MINECO/European FEDER Funds grants PI17-00048, PI20-00057 (to C.U.), and PI18-01374 (to M.A.M.); by Comunidad Autónoma de Madrid/ERDF-ESF grant S2018/BAA-4403 (to C.U.); by Association Française contre les Myopathies (AFM) grant 16086 (to E.F.-V.); by Fondazione Telethon-Cariplo grant GJC21014 (to E.F.-V.); by Research Council of Norway (288164), Bergen Research Foundation (BFS2017REK05), and Western Norway Regional Health Authority (F-11470) (to C.T.); by a Clinician Scientist Fellowship (MR/S002065/1) and Strategic Award (MR/S005021/1) from Medical Research Council (MRC, UK) (to R.D.S.P.); by a Core Grant from MRC (MC_UU_00015/5), an Advanced Grant from the European Research Council (ERC) (MITCARE: FP7-322424), Mitofight Grant—Associazione Renato Comini Onlus, and NRJ Institut de France Grant (to M.Z.); and by the Australian National Health and Medical Research Council (NHMRC project grants #1165217 and #1164459 to M.T.R., #1125390 and #1140906 to D.A.S. and M.T.R., and NHMRC Fellowship 1140851 to D.A.S.)., Peer reviewed